Tanshinone IIA Suppresses Gastric Cancer Cell Proliferation and Migration by Downregulation of FOXM1

Overview

Journal Oncol Rep

Specialty Oncology

Date 2017 Feb 11

PMID 28184921

Citations 24

Authors

Jiao Yu

Xiaoxia Wang

Yuhua Li

Bin Tang

Affiliations

Soon will be listed here.

Abstract

Tanshinone IIA (TSN) exhibits a variety of anticancer effects. However, whether it inhibits gastric cancer (GC) cell proliferation and migration and the mechanism remain unclear. In the present study, different concentrations of TSN were co-incubated with SGC-7901 cells. The pcDNA-FOXM1 or FOXM1-siRNA plasmid was transfected into cells before treatment with 5 µg/l TSN. The proliferation and migration abilities of the SGC-7901 cells were tested by MTT and wound healing assays. Western blotting was used to investigate the expression levels of P21, Ki-67, PCNA, MMP-2, MMP-9 and FOXM1. We found that compared with the control, the proliferation and migration abilities of the SGC-7901 cells were decreased after incubation with different concentrations of TSN in a dose-dependent manner (p<0.01). Moreover, the expression levels of Ki-67, PCAN, MMP-2, MMP-9 and FOXM1 were decreased, and P21 was increased in the TSN-treated SGC-7901 cells (p<0.01). In addition, downregulation of FOXM1 by FOXM1-siRNA had the same effect as TSN on SGC-7901 cells, and overexpression of FOXM1 partly abrogated TSN-mediated inhibition of SGC-7901 cell proliferation and migration. These results suggested that TSN inhibits SGC-7901 cell proliferation and migration by downregulation of FOXM1.

Citing Articles

Signaling pathways behind the biological effects of tanshinone IIA for the prevention of cancer and cardiovascular diseases.

Shahrokhi H, Asili J, Tayarani-Najaran Z, Boozari M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39937254 DOI: 10.1007/s00210-025-03857-x.

Natural products targeting ferroptosis pathways in cancer therapy (Review).

Na X, Li L, Liu D, He J, Zhang L, Zhou Y Oncol Rep. 2024; 52(3).

PMID: 39054952 PMC: 11292301. DOI: 10.3892/or.2024.8782.

The mechanisms of tanshinone in the treatment of tumors.

Zhang P, Liu W, Wang Y Front Pharmacol. 2023; 14:1282203.

PMID: 37964867 PMC: 10642231. DOI: 10.3389/fphar.2023.1282203.

Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy.

Alam S, Samanta A, Uddin F, Ali S, Hoque M Pharmacol Rep. 2023; 75(4):907-922.

PMID: 37440106 DOI: 10.1007/s43440-023-00507-y.

Tanshinone IIA (TSIIA) represses the progression of non-small cell lung cancer by the circ_0020123/miR-1299/HMGB3 pathway.

Sun F, Yang X, Song W, Yu N, Lin Q Mol Cell Biochem. 2022; 478(9):1973-1986.

PMID: 36586093 DOI: 10.1007/s11010-022-04646-3.

References

Zhang Y, Li C, Ma L, Ding M, Zhang B . MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer. Int J Oncol. 2016; 49(3):1068-80. DOI: 10.3892/ijo.2016.3581. View

Jing X, Xu Y, Cheng W, Guo S, Zou Y, He L . Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers. Cancer Chemother Pharmacol. 2016; 77(6):1171-81. DOI: 10.1007/s00280-016-3034-6. View

Zhang N, Xie Y, Li B, Ning Z, Wang A, Cui X . FoxM1 influences mouse hepatocellular carcinoma metastasis in vitro. Int J Clin Exp Pathol. 2015; 8(3):2771-8. PMC: 4440092. View

Tan X, Yang Y, Cheng J, Li P, Inoue I, Zeng X . Unique action of sodium tanshinone II-A sulfonate (DS-201) on the Ca(2+) dependent BK(Ca) activation in mouse cerebral arterial smooth muscle cells. Eur J Pharmacol. 2011; 656(1-3):27-32. DOI: 10.1016/j.ejphar.2011.01.028. View

Xu S, Little P, Lan T, Huang Y, Le K, Wu X . Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys. 2011; 515(1-2):72-9. DOI: 10.1016/j.abb.2011.08.006. View

Sanders D, Ross-Innes C, Beraldi D, Carroll J, Balasubramanian S . Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol. 2013; 14(1):R6. PMC: 3663086. DOI: 10.1186/gb-2013-14-1-r6. View

Lin J, Ke Y, Lai J, Ho T . Tanshinone IIA enhances the effects of TRAIL by downregulating survivin in human ovarian carcinoma cells. Phytomedicine. 2015; 22(10):929-38. DOI: 10.1016/j.phymed.2015.06.012. View

Gormally M, Dexheimer T, Marsico G, Sanders D, Lowe C, Matak-Vinkovic D . Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014; 5:5165. PMC: 4258842. DOI: 10.1038/ncomms6165. View

Wang C, Hua L, Sun J, Yao K, Chen J, Zhang J . MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp Pathol. 2016; 8(11):14013-20. PMC: 4713499. View

10.

Wang C, Du X, Yang R, Liu J, Xu D, Shi J . The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats. J Steroid Biochem Mol Biol. 2014; 145:28-37. DOI: 10.1016/j.jsbmb.2014.09.026. View

11.

Wang Y, Li J, Wang Y, Miao Z . Tanshinone I inhibits tumor angiogenesis by reducing Stat3 phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. Oncotarget. 2015; 6(18):16031-42. PMC: 4599254. DOI: 10.18632/oncotarget.3648. View

12.

Lu M, Wang C, Wang J . Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways. Int J Oncol. 2016; 49(2):603-10. DOI: 10.3892/ijo.2016.3565. View

13.

Kim E, Kang S, Im C, Lee J, Ahn K, Yang W . Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction. Int J Oncol. 2016; 48(5):2205-12. DOI: 10.3892/ijo.2016.3441. View

14.

Kim H, Cho Y, Kang H, Yim Y, Kim S, Song J . Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget. 2016; 7(31):49902-49916. PMC: 5226556. DOI: 10.18632/oncotarget.10231. View

15.

Buchner M, Park E, Geng H, Klemm L, Flach J, Passegue E . Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun. 2015; 6:6471. PMC: 4366523. DOI: 10.1038/ncomms7471. View

16.

Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J . Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer. 2005; 116(5):799-807. DOI: 10.1002/ijc.20880. View

17.

Qiu S, Granet R, Mbakidi J, Bregier F, Pouget C, Micallef L . Delivery of tanshinone IIA and α-mangostin from gold/PEI/cyclodextrin nanoparticle platform designed for prostate cancer chemotherapy. Bioorg Med Chem Lett. 2016; 26(10):2503-2506. DOI: 10.1016/j.bmcl.2016.03.097. View

18.

Ahmed M, Hussain A, Siraj A, Uddin S, Al-Sanea N, Al-Dayel F . Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Mol Cancer. 2015; 14:131. PMC: 4861127. DOI: 10.1186/s12943-015-0406-1. View

19.

Yu Z, Wang J, Wu X, Xie H, Han Y, Guan Y . Tanshinone IIA Prevents Rat Basilar Artery Smooth Muscle Cells Proliferation by Inactivation of PDK1 During the Development of Hypertension. J Cardiovasc Pharmacol Ther. 2015; 20(6):563-71. DOI: 10.1177/1074248415574743. View

20.

Kanda M, Shimizu D, Fujii T, Tanaka H, Shibata M, Iwata N . Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. Int J Oncol. 2016; 49(3):1195-202. DOI: 10.3892/ijo.2016.3584. View